Bristol Myers Squibb Commits $2.3 Billion to New Texas Manufacturing Campus

What happened

Bristol Myers Squibb announced plans to invest $2.3 billion in a new manufacturing campus in Houston, Texas, expanding its U.S. production capabilities. The investment is positioned to support future pipeline therapies and enhance supply chain resilience. While the move signals management’s long-term confidence, it adds to near-term capital expenditures at a time when policy pressures and legacy portfolio erosion are squeezing margins. The campus is unlikely to contribute revenue for several years, leaving the immediate focus on the 2026 Eliquis bridge and Revlimid’s volume-cap removal. The announcement reinforces the company’s commitment to domestic manufacturing but does little to change the current thesis, which hinges on observable margin and revenue stability over the next two quarters.

Implication

Longer-term, the Houston campus strengthens BMY’s ability to scale production for its Growth Portfolio and future launches, potentially improving operating leverage once capacity is fully utilized; however, the payoff is years away and does not mitigate the near-term risks from IRA pricing and LOE events.

Thesis delta

The announcement does not materially alter the investment thesis. The catalyst timeline remains focused on Q1–Q2 2026 gross margin and Eliquis performance, and the added capex heightens the need for operational execution. No change to the WAIT rating.